Compare Abeona Therapeutics Inc (ABEO) vs Ishares Msci Italy ETF (EWI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Ishares Msci Italy ETF — how do they compare? Abeona Therapeutics Inc trades at $6.75 (market cap $373.32M), while Ishares Msci Italy ETF trades at $60.07. Which is the better fit depends on your goals.
| ABEO | EWI | |
|---|---|---|
Market Cap | $373.32M | — |
Sector | Health | Broad Market / Factor |
52-Week High | $7.23 | $61.14 |
52-Week Low | $4.17 | $47.32 |
Enterprise Value | $228.22M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
EWI trades at $61.14, up 0.84% today, with a bullish technical signal driven by moving averages. The stock recently hit a 52-week high (Zacks Investment Research, 2026-06-10), supported by improving Italian industrial data. A dividend of $1.17 is scheduled for payment on June 18, 2026. However, key valuation ratios like P/E and P/S are unavailable, limiting fundamental clarity.
Outlook is mixed: technical strength and European equity inflows (Proactive Investors, 2026-07-07) offer upside, but stagflation risks in Italy (Seeking Alpha, 2026-06-04) and ECB rate hikes (Bloomberg, 2026-06-11) pose headwinds. Investors should weigh bullish momentum against macroeconomic uncertainties and incomplete financial data.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Ishares Msci Italy ETF
EWI is a country-specific ETF that tracks the performance of the Italian equity market. It provides targeted access to large and mid-sized companies in Italy, with a heavy focus on the financial sector and holdings like UniCredit and Intesa Sanpaolo.
Read more on EWI →
